Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money

76% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

  • Updates
  • disruptive innovation

Top Stories

AstraZeneca buys CinCor for $1.8bn

In today’s top stories, Apple and Mercedes-Benz reveal their plans to target India, semiconductor firm AMD reveals AI chips, and AstraZeneca secures its latest M&A deal. Evercore analysts pick the tech stocks to watch in 2023 and Alibaba’s share price jumps as co-founder Jack Ma gives up control of Ant Group.

Apple and Mercedes-Benz eye India opportunity

Big firms have their sights set on India in 2023. Mercedes-Benz [MBG.DE] is expecting double-digit growth this year, despite concerns that a weak rupee could push up car prices. The automaker has also announced it plans to launch 10 new models, including electric vehicles (EVs). Meanwhile, Apple [AAPL] is hiring retail staff amid a push that includes plans to open its first flagship stores in the country.

AI chips could boost PC demand

The Advanced Micro Devices [AMD] share price plunged in 2022 as demand for PCs worsened – a situation president and CEO Lisa Su described as messy” on the Q3 2022 earnings call in November. Now, the chipmaker is hoping that PCs powered by AI will help demand to recover. At AMDs CES 2023 press conference, the company discussed how its new Ryzen 7000 mobile processors will be the first chips of their kind with a dedicated AI engine.

AstraZeneca buys blood pressure drugmaker

UK pharmaceutical giant AstraZeneca [AZN.L] has agreed to buy clinical-stage biopharmaceutical CinCor [CINC] for $1.8bn or $26 per share, a 120.7% premium on the 6 January closing price of $11.78. CinCors blood pressure drug is used in treatment-resistant cases of hypertension and will be added to AstraZenecas cardiorenal pipeline. Acquisitions are a key part of AstraZenecas growth and innovation strategy through 2025, in an effort to build on its success with Covid-19 vaccines.

Evercores tech picks for 2023

After a rough 2022, the tech-heavy Nasdaq Composite ended the first trading week of the year marginally higher. While tech-focused investors should remain cautious, Evercore ISI head of research Mark Mahaney is bullish on the sector. We have seen a good number of companies take cost actions [and] reduce their workforces to better manage their costs. So theres a good set-up here,” Mahaney told CNBC. His top picks are Netflix [NFLX], Uber [UBER] and Wix [WIX].

Jack Ma cedes control of Ant Group

Hong Kong-listed shares of the ecommerce giant Alibaba [BABA] closed 8.7% higher yesterday following the announcement over the weekend that co-founder Jack Ma is ceding control of Ant Group. The move may lead to Beijings regulators looking upon the fintech more favourably, but listing rules mean its highly-anticipated IPO will now be delayed further. An Ant spokesperson told Reuters its current focus is on business optimisation.

Disclaimer Past performance is not a reliable indicator of future results.

CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.

The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.

CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.

*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.

Continue reading for FREE

  • Includes free newsletter updates, unsubscribe anytime. Privacy policy

Latest articles